Imipenem-Cilastatin sodium hydrate

Base Information

• Chemical Name: Imipenem-Cilastatin sodium hydrate
• CAS No.: 92309-29-0
• Molecular Formula: C28H43N5O9S2
• Molecular Weight: 697.8
• Hs Code.: 3003209000
• Mol file: 92309-29-0.mol

Synonyms:Tienam 500;Primaxin;1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,6-[(1R)-1-hydroxyethyl]-3-[[2-[(iminomethyl) amino]ethyl]thio]-7-oxo-,(5R,6S)-,mixt. with (2Z)-7-[[(2R)-2-amino-2-carboxyethyl] thio]-2-[[[(1S)-2,2-dimethylcyclopropyl]- carbonyl]amino]-2-heptenoic acid;Primaxin (TN);sodium; (Z)-7-[(2R)-2-amino-2-carboxy-ethyl]sulfanyl-2-[[(1S)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoate; (5R,6S)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-(1-hydroxyethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid;MK 787-MK 791 mixture;Tainem;Imipenem-cilastatin;Tienam (TN);1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-((1R)-1-hydroxyethyl)-3-((2-((iminomethyl)amino)ethyl)thio)-7-oxo-, (5R,6S)-, mixt. with (2Z)-7-(((2R)-2-amino-2-carboxyethyl)thio)-2-((((1S)-2,2-dimethylcyclopropyl)carbonyl)amino)-2-heptenoic acid;85960-17-4;MK 0787-MK 0791 mixture;1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-3-((2-((iminomethyl)amino)ethyl)thio)-7-oxo-, (5R-(5alpha,6alpha(R*)))-, mixt. with (R-(R*,S*-(Z)))-7-((2-amino-2-carboxyethyl)thio)-2-(((2,2-dimethylcyclopropyl)carbonyl)amino)-2-heptanoic acid;MK-0787 / MK-0791 (1:1);7-[(2S)-2-amino-2-carboxy-ethyl]sulfanyl-2-[[(1S)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoic acid; (5R)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-(1-hydroxyethyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid;Thienam;Imipenem/Cilastatin Sodium;

Chemical Property of Imipenem-Cilastatin sodium hydrate

Chemical Property:

• Vapor Pressure: 7.13E-19mmHg at 25°C
• Boiling Point: 990.4 °C at 760 mmHg
• Flash Point: 552.8 °C
• PSA: 308.60000
• LogP: 1.37730

Purity/Quality:

99% ^*data from raw suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Drug interactions: Potentially hazardous interactions with other drugs Antiepileptics: reduced valproate concentration - avoid. Antivirals: convulsions reported with concomitant administration of ganciclovir and valganciclovir. Ciclosporin: variable reports of increase / no change in ciclosporin levels, and of neurotoxicity.